JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients

被引：0
作者：
Serena Delbue
Francesca Elia
Camilla Carloni
Valentina Pecchenini
Diego Franciotta
Matteo Gastaldi
Elena Colombo
Lucia Signorini
Silvia Carluccio
Anna Bellizzi
Roberto Bergamaschi
Pasquale Ferrante
机构：
[1] University of Milano,Department of Biomedical Surgical and Dental Sciences
[2] Laboratory of Translational Research Fondazione Ettore Sansavini,Department of General Neurology
[3] National Neurological Institute C. Mondino,Department of Public Health and Infectious Diseases
[4] Sapienza University,undefined
[5] Istituto Clinico Città Studi,undefined
来源：
Journal of NeuroVirology | 2015年 / 21卷
关键词：
Natalizumab; JC virus; Multiple sclerosis; Urinary excretion; Seroprevalence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The risk of developing progressive multifocal leukoencephalopathy (PML), as a consequence of infection/reactivation with JC virus (JCV), is consistent in natalizumab-treated multiple sclerosis (MS) patients, with 430 cases of PML reported so far. The risk of PML is higher in JCV seropositive patients, and it is recommended that only MS patients without JCV antibodies should be enrolled in the treatment postulating that they do not have JCV infection.
引用
收藏
页码：645 / 652
页数：7
相关论文
共 270 条
  • [1] Berger JR(2012)The pathogenesis of progressive multifocal leukoencephalopathy Discov Med 12 495-503
  • [2] Khalili K(2013)JC virus antibody status underestimates infection rates Ann Neurol 74 84-90
  • [3] Berger JR(2012)Risk of natalizumab-associated progressive multifocal leukoencephalopathy N Engl J Med 366 1870-1880
  • [4] Houff SA(2009)Asymptomatic reactivation of JC virus in patients treated with natalizumab N Engl J Med 361 1067-1074
  • [5] Gurwell J(2010)Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases Lancet Neurol 9 438-446
  • [6] Vega N(2005)A case of a PML patient with four different JC virus TCR rearrangements in CSF, blood, serum and urine J Neurovirol 11 51-57
  • [7] Miller CS(2007)JCV viremia in interferon-beta treated and untreated Italian multiple sclerosis patients and healthy controls J Neurovirol 13 77-78
  • [8] Danaher RJ(2013)Predicting PML in natalizumab-treated patients: can we do better? J Neurol Neurosurg Psychiatry 84 1182-1183
  • [9] Bloomgren G(2013)Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish multiple sclerosis patients treated with natalizumab J NeuroImmune Pharm 8 1277-86
  • [10] Richman S(1994)Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals Virology 198 59-70
12345678910